AU2003286499A8 - Interference with c-maf function in multiple myeloma - Google Patents

Interference with c-maf function in multiple myeloma

Info

Publication number
AU2003286499A8
AU2003286499A8 AU2003286499A AU2003286499A AU2003286499A8 AU 2003286499 A8 AU2003286499 A8 AU 2003286499A8 AU 2003286499 A AU2003286499 A AU 2003286499A AU 2003286499 A AU2003286499 A AU 2003286499A AU 2003286499 A8 AU2003286499 A8 AU 2003286499A8
Authority
AU
Australia
Prior art keywords
interference
multiple myeloma
maf
function
maf function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286499A
Other versions
AU2003286499A1 (en
Inventor
Louis M M D Staudt Ph D
Elaine Hurt
Michael Kuehl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2003286499A1 publication Critical patent/AU2003286499A1/en
Publication of AU2003286499A8 publication Critical patent/AU2003286499A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
AU2003286499A 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma Abandoned AU2003286499A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/033162 WO2005046731A1 (en) 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma

Publications (2)

Publication Number Publication Date
AU2003286499A1 AU2003286499A1 (en) 2004-06-06
AU2003286499A8 true AU2003286499A8 (en) 2005-06-06

Family

ID=34589281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286499A Abandoned AU2003286499A1 (en) 2003-10-17 2003-10-17 Interference with c-maf function in multiple myeloma

Country Status (2)

Country Link
AU (1) AU2003286499A1 (en)
WO (1) WO2005046731A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822440B2 (en) 2006-10-10 2014-09-02 Mayo Foundation For Medical Education And Research Inhibiting cyclin D polypeptides
CN103339265B (en) 2010-10-06 2018-03-30 生物医学研究机构私人基金会 Method for the diagnosis of Metastasis in Breast Cancer, prognosis and treatment
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (en) 2012-06-06 2019-03-22 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
US20150218213A1 (en) * 2012-09-04 2015-08-06 Università Degli Studi Di Torino Inhibitors of alpha6 integrin/e-cadherin complex
EP2703005A1 (en) * 2012-09-04 2014-03-05 Università Degli Studi Di Torino Inhibitors of alpha6 Integrin/E-Cadherin Complex
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
BR112015008255B1 (en) 2012-10-12 2023-02-28 Inbiomotion S.L IN VITRO METHODS FOR DIAGNOSIS OR PROGNOSIS OF BONE METASTASIS IN AN INDIVIDUAL WITH PROSTATE CANCER AND METHOD FOR CLASSIFIING AN INDIVIDUAL SUFFERING FROM PROSTATE CANCER IN A COHORT
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
EP3524698A1 (en) 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the prognosis and treatment of cancer metastasis
MX2017007381A (en) 2014-12-11 2017-11-06 Inbiomotion Sl Binding members for human c-maf.
EP3090751A1 (en) 2015-05-06 2016-11-09 Université de Lausanne Molecular profiling of cd8 t-cells in autochthonous melanoma identifies maf as driver of exhaustion
WO2017203468A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
BR112020010192A2 (en) 2017-11-22 2020-10-13 Inbiomotion S.L. therapeutic treatment of breast cancer based on c-maf status

Also Published As

Publication number Publication date
WO2005046731A1 (en) 2005-05-26
AU2003286499A1 (en) 2004-06-06

Similar Documents

Publication Publication Date Title
GB0325143D0 (en) Datacasting
ZA200602792B (en) Multigame selection
HK1083476A1 (en) Multiple spplicator
AU2003286499A8 (en) Interference with c-maf function in multiple myeloma
GB0311208D0 (en) Feature based caricaturing
EP1628919A4 (en) Improved solar still
GB2421742B (en) Structural arrangement
GB0308128D0 (en) Concentrator
GB0305873D0 (en) Get into bed - chair
EP1608076A4 (en) Access point
GB0330215D0 (en) Helicar
GB2418132B (en) Epaulette
GB0324330D0 (en) Mini-gym
AU2750P (en) Balablue Sutera cordata
AU2833P (en) Baltinrose Gaura lindheimeri
AU2834P (en) Baltinblus Gaura lindheimeri
GB0305945D0 (en) Sun strip
GB0317347D0 (en) Drawing
GB0314290D0 (en) Sun strips
AU153034S (en) Hatbox with lid
AU151958S (en) Carrier
PL114016U1 (en) Small armchair-potty
GB0316917D0 (en) Type II pipkinase
GB0314445D0 (en) Representative instances
TW572070U (en) Reboundable delelineator background

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 19, NO 28, PAGE(S) 1859 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2003286499, UNDER INID (43) CORRECT THE DATE TO READ 06.06.2005

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase